AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
According to Kristen Ghodsee, the triumphalist attitudes of Western powers at the end of the Cold War and the fixation with linking all leftist and socialist ideals with the excesses of Stalinism allowed neoliberalism to fill the void. This undermined democratic institutions and reforms, leaving a trail of economic misery, unemployment, hopelessness and rising economic inequality throughout the former Eastern Bloc and much of the West in the following decades. With democracy weakened and the anti-capitalist left marginalised, the anger and resentment which followed the period of neoliberalism was channeled into extremist nationalist movements in both the former and the latter.
== Effectors == Each Rho protein affects numerous proteins downstream, all of which having roles in various cell processes. Over 60 targets of the three common Rho GTPases have been found. Two molecules that directly stimulate actin polymerization are the Arp2/3 proteins and the Diaphanous-related formins.
Beta decay would reduce competition and would result in alpha decay remaining the dominant decay channel, unless additional stability towards alpha decay exists in superdeformed isomers of these nuclides.
=== NIA T32 Training Program for Research Scientists in the Biology of Aging === The NIA T32 Training Program for Research Scientists in the Biology of Aging is one of the nation's premier institutional training programs dedicated to preparing the next generation of leaders in geroscience. Established through support from the National Institute on Aging (NIA), the program provides rigorous multidisciplinary research training for both predoctoral (PhD and MD/PhD) students and postdoctoral fellows pursuing careers in the basic, translational, and clinical biology of aging. For more than three decades, the program has trained investigators who have gone on to become independent scientists, faculty members, and leaders in academia, government, and industry, significantly contributing to advances in aging biology and age-related disease research. The overarching goal of the training program is to develop independent investigators capable of translating discoveries in the fundamental biology of aging into interventions that improve healthspan and reduce the burden of age-associated diseases. Trainees receive individualized, mentor-guided research experiences that integrate molecular, cellular, organismal, and translational approaches to understanding the mechanisms that drive biological aging. The curriculum emphasizes the principles of geroscience—the concept that targeting the biological processes of aging can simultaneously delay or prevent multiple chronic diseases—providing trainees with a broad scientific foundation while encouraging innovative, interdisciplinary research.
Sources: en.wikipedia.org
Participation in rehabilitation programs during the early to middle stage of the disease may be beneficial as it translates into long-term maintenance of motor and functional performance. Rehabilitation during the late stage aims to compensate for motor and functional losses. For long-term independent management, the therapist may develop home exercise programs for appropriate people. Palliative care may also improve quality of life for people with HD by treating the symptoms and psychological stress of having a progressive degenerative disease.
=== Assay === Fluid dripping from the nose (CSF rhinorrhoea) or ears (CSF otorrhea) should be collected and tested for the protein beta-2 transferrin which would be highly accurate in identifying CS fluid and diagnosing a cranial CSF leak.
Positron emission tomography imaging studies have reportedly found that tramadol levels are at least four-fold higher in the brain than in plasma. Conversely, brain levels of desmetramadol "only slowly approach those in plasma". The plasma protein binding of tramadol is only 4–20%; hence, almost all tramadol in circulation is free, thus bioactive.
Sources: en.wikipedia.org
Carbon dioxide is the lasing medium in a carbon-dioxide laser, which is one of the earliest type of lasers. Carbon dioxide can be used as a means of controlling the pH of swimming pools, by continuously adding gas to the water, thus keeping the pH from rising. Among the advantages of this is the avoidance of handling (more hazardous) acids. Similarly, it is also used in the maintaining reef aquaria, where it is commonly used in calcium reactors to temporarily lower the pH of water being passed over calcium carbonate in order to allow the calcium carbonate to dissolve into the water more freely, where it is used by some corals to build their skeleton. Used as the primary coolant in the British advanced gas-cooled reactor for nuclear power generation. Carbon dioxide induction is commonly used for the euthanasia of laboratory research animals. Methods to administer CO2 include placing animals directly into a closed, prefilled chamber containing CO2, or exposure to a gradually increasing concentration of CO2. The American Veterinary Medical Association's 2020 guidelines for carbon dioxide induction claim that a displacement rate of 30–70% of the chamber or cage volume per minute is optimal for the euthanasia of small rodents. Percentages of CO2 vary for different species, based on identified optimal percentages claimed to minimize distress. Carbon dioxide is also used in several related cleaning and surface-preparation techniques.
== History == In 1976, the first Old Chicago taphouse opened in Boulder, Colorado. The first Gordon Biersch Brewery Restaurant was opened in Palo Alto, California on July 6, 1988. The first Rock Bottom restaurant opened in Denver, Colorado in 1991. In 1993, Big River Breweries opened its first location in Chattanooga, Tennessee. Rock Bottom Restaurants, Inc., made an initial public offering in 1994. In 1995, the first ChopHouse opened in Denver, Colorado. Big River Breweries opened the only brewpub at Walt Disney World in 1996. A private management buyout took Rock Bottom Restaurants, Inc. private in 1999. In the same year, Gordon Biersch was acquired by Big River Breweries. In 2000, Rock Bottom Restaurants formed the Rock Bottom Foundation, a 501(c)(3) non-profit entity. Rock Bottom Restaurants laid off about 20% of its corporate staff in 2007 and slowed its growth plans along with ceasing its search for an equity partner. In 2010, Rock Bottom Restaurants and Gordon Biersch Brewery Restaurant Group were acquired by Centerbridge Capital Partners and merged to form CraftWorks Restaurants and Breweries, Inc. On November 1, 2018, CraftWorks announced that it had acquired Logan's Roadhouse and formed Craftworks Holdings. Logan's Roadhouse is a chain of restaurants founded in 1991 in Lexington, Kentucky. The chain's menu includes mesquite-grilled steaks, traditional American fare (sandwiches, soup, salads, and seafood), ice-cold longneck beer, and homemade yeast rolls. On June 12, 2020, Craftworks was purchased by SPB Hospitality for $93 million.
To date it is still under debate whether the base complex assembles separately, whether the assembly is templated by the 20S core particle, or whether alternative assembly pathways exist. In addition to the four assembly chaperones, the deubiquitinating enzyme Ubp6/Usp14 also promotes base assembly, but it is not essential. The lid assembles separately in a specific order and does not require assembly chaperones.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.